US Stock Futures Edge Higher Ahead Of Economic Data

Pre-open movers US stock futures traded higher in early pre-market trade. The Chicago PMI for November will be released at 9:45 a.m. ET, while pending home sales index for October will be released at 10:00 a.m. ET. The Dallas Fed manufacturing index for November will be released at 10:30 a.m. ET. Futures for the Dow Jones Industrial Average surged 19.5 points to 17,820.5, while the Standard & Poor's 500 index futures rose 1.50 points to 2,091.50. Futures for the Nasdaq 100 index gained 10.25 points to 4,692.75. A Peek Into Global Markets European markets were higher today, with the Spanish Ibex Index rising 0.90 percent, STOXX Europe 600 Index surging 0.46 percent and German DAX 30 index gaining 1.01 percent. French CAC 40 Index climbed 0.73 percent and London's FTSE 100 Index rose 0.01 percent. In Asian markets, Japan's Nikkei Stock Average fell 0.69 percent, Hong Kong's Hang Seng Index fell 0.33 percent, China's Shanghai Composite Index surged 0.26 percent and India's BSE Sensex jumped 0.07 percent. Broker Recommendation Analysts at Barclays upgraded Fitbit Inc FIT from Equal-weight to Overweight. The price target for Fitbit is set to $49. Fitbit shares closed at $27.80 on Friday. Breaking news

• Teva Pharmaceutical Industries Ltd. TEVA and Takeda Pharmaceutical Company Limited TKPYY today announced that the two companies have entered into a definitive agreement to establish an unprecedented partnership in Japan. To read the full news, click here.
• LyondellBasell LYB today announced that it has entered into a definitive agreement to acquire the polypropylene (PP) compounding assets of Zylog Plastalloys Pvt. Ltd. (Zylog) of India. To read the full news, click here.
• Carriage Services, Inc. CSV announced the acquisition of Bright Funeral Home & Cremation Center, the prominent funeral services provider in Wake Forest, North Carolina, which was originally established in 1964 by Betty Bright, the Bright family matriarch. To read the full news, click here.
• Horizon Pharma plc HZNP today announced that the European Commission (EC) has adopted a binding decision to approve RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid for use as an adjunctive therapy for chronic management of adult and pediatric patients two months of age and older with six subtypes of Urea Cycle Disorders (UCDs). To read the full news, click here.